Management Medications

Medications to lower triglycerides 26

If lifestyle changes have not lowered your triglyceride levels enough, you and your doctor may discuss prescription medications shown to lower triglyceride levels.

These prescription medications do not cure the problems that cause high triglycerides, so you may need to keep taking medications for long-term maintenance. The following may reduce triglyceride levels in some people:

  • Fibrates
  • Statins
  • Niacin (vitamin B3)
  • Prescription-quality omega-3 fatty acids

All medications can cause side effects or interact with other medications, so they should be used cautiously, only as prescribed by your doctor, and only under the close supervision of your healthcare team.

Repeat testing of triglyceride levels  15

Triglyceride levels can change rapidly and have large variations from one test to the next. Your doctor may need to order frequent testing of your triglyceride levels to see if treatments work or if your triglyceride levels become dangerously high sometimes. Your triglyceride levels may also be affected by a recent meal.

What research is being done to find better treatments for severe hypertriglyceridemia (sHTG)?

Researchers are studying several investigational drugs to determine if they will lower triglyceride levels, as well as lower the risk of pancreatitis or cardiovascular disease in people with sHTG.

Are there investigational drugs being studied for people with familial chylomicronemia syndrome (FCS)?

Yes, separate studies are studying investigational drugs in people with FCS.

Learn more about ongoing FCS studies.

Show References
 
  • 1. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99-109c.
  • 2. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791-806.
  • 3. Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, et al. 2021 ACC Expert Consensus Decision Pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021.
  • 4. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-35.
  • 5. Packard CJ. Remnants, LDL, and the quantification of lipoprotein-associated risk in atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2022;24(1534-6242 (Electronic)):133-42.
  • 6. Wang Y. Higher fasting triglyceride predicts higher risks of diabetes mortality in US adults. Lipids Health Dis. 2021;20(1):181.
  • 7. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350.
  • 8. Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80-5.
  • 9. National Lipid Association. Lifestyle changes to reduce triglycerides: Advice from the National Lipid Association Clinician’s Lifestyle Modification Toolbox. https://www.lipid.org/sites/default/files/lifestyle_changes_to_reduce_triglycerides.final_edits.7.17.16_0.pdf.
  • 10. Santos-Baez LS, Ginsberg HN. Hypertriglyceridemia-causes, significance, and approaches to therapy. Front Endocrinol (Lausanne). 2020;11:616.
  • 11. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: Triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 2019;40(2):537-57.
  • 12. Carrasquilla GD, Christiansen MR, Kilpeläinen TO. The genetic basis of hypertriglyceridemia. Curr Atheroscler Rep. 2021;23(8):39.
  • 13. Dron JS, Dilliott AA, Lawson A, McIntyre AD, Davis BD, Wang J, et al. Loss-of-function CREB3L3 variants in patients with severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2020;40(8):1935-41.
  • 14. Javvaji A, Can AS, Sharma S. Dysbetalipoproteinemia. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023, StatPearls Publishing LLC.; 2023.
  • 15. Moulin P, Dufour R, Averna M, Arca M, Cefalù AB, Noto D, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". Atheroscler. 2018;275:265-72.
  • 16. Nawaz H, Koutroumpakis E, Easler J, Slivka A, Whitcomb DC, Singh VP, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110(10):1497-503.
  • 17. Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1-7.
  • 18. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.
  • 19. Koehler EM, Schouten JN, Hansen BE, Hofman A, Stricker BH, Janssen HL. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clin Gastroenterol Hepatol. 2013;11(9):1201-4.
  • 20. Nivukoski U, Niemelä M, Bloigu A, Bloigu R, Aalto M, Laatikainen T, et al. Combined effects of lifestyle risk factors on fatty liver index. BMC Gastroenterol. 2020;20(1):109.
  • 21. Paquette M, Bernard S. The evolving story of multifactorial chylomicronemia syndrome. Front Cardiovasc Med. 2022;9:886266.
  • 22. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009;14(4):257-67.
  • 23. Benefits of physical activity: Center for Disease Control and Prevention. [https://www.cdc.gov/physicalactivity/basics/pa-health/index.htm.
  • 24. Tari AR, Nauman J, Zisko N, Skjellegrind HK, Bosnes I, Bergh S, et al. Temporal changes in cardiorespiratory fitness and risk of dementia incidence and mortality: a population-based prospective cohort study. Lancet Public Health. 2019;4(11):e565-e74.
  • 25. Whole person health: What you need to know: National Center for Complementary and Integrative Health. [https://www.nccih.nih.gov/health/whole-person-health-what-you-need-to-know.
  • 26. Berglund L, Brunzell J, Sacks FM. Patient information page from The Hormone Foundations. Patient guide to the assessment and treatment of hypertriglyceridemia (high triglycerides). J Clin Endocrinol Metab. 2012;97(9):31a-2a.
  • 27. Ito MK. Chapter 6. Patient-centered care. In: Gogia S, editor. Fundamentals of Telemedicine and Telehealth: Academic Press; 2020:115-126.
  • 28. Barry MJ, Edgman-Levitan S. Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780-1.
  • 29. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361-7.
  • 30. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2. J Clin Lipidol. 2015;9(6 Suppl):S1-122.e1.
  • 31. Banerji A, Anderson J, Johnston DT. Optimal management of hereditary angioedema: Shared decision-making. J Asthma Allergy. 2021;14:119-25.
  • 32. Zeman H, Cavanaugh E, Metallinos-Katsaras E, Ireland K, Pojednic R. Improved long-term outcomes in high-risk patients receiving registered dietitian nutritionist care. Endocr Metab Sci. 2021;2:100078.
  • 33. Morrell J, Wierzbicki T. 10 Steps before you refer for: Lipids. Br J Cardiol. 2009;16:242-5.
  • 34. Davidson M, Stevenson M, Hsieh A, Ahmad Z, Roeters van Lennep J, Crowson C, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018;12(4):898-907.e2.
  • 35. Lipid Panel: Cleveland Clinic. [https://my.clevelandclinic.org/health/diagnostics/17176-lipid-panel.
  • 36. Academy of Nutrition and Dietetics. Medical nutrition therapy (MNT) systematic review [https://www.andeal.org/topic.cfm?menu=3949.

Your are about to leave KnowYourTGs.com

You will be taken to a website independently operated and not managed by Ionis Pharmaceuticals. Ionis Pharmaceuticals assumes no responsibility for the content of the site.

Thank you for visiting KnowYourTGs.com